摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-[4-(苯基甲氧基)苯氧基]丙烷-1,2-二醇 | 108840-40-0

中文名称
3-[4-(苯基甲氧基)苯氧基]丙烷-1,2-二醇
中文别名
十醛
英文名称
1-(4-benzyloxy-phenoxy)-2S,3-dihydroxy-propane
英文别名
3-[4-(phenylmethoxy)phenoxy]-1,2-propanediol;3-(4-benzyloxy-phenoxy)-propane-1,2-diol;3-(4-Benzyloxy-phenoxy)-propan-1,2-diol;1-(4-Benzyloxyphenoxy)-2S,3-dihydroxypropan;3-(p-Benzyloxyphenoxy)-1,2-propanediol;3-(4-phenylmethoxyphenoxy)propane-1,2-diol
3-[4-(苯基甲氧基)苯氧基]丙烷-1,2-二醇化学式
CAS
108840-40-0
化学式
C16H18O4
mdl
——
分子量
274.317
InChiKey
CLZPEXPWVLNWBT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    20
  • 可旋转键数:
    7
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    58.9
  • 氢给体数:
    2
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2909499000

SDS

SDS:a6236d78b527572e71aa2a355702962f
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-[4-(苯基甲氧基)苯氧基]丙烷-1,2-二醇吡啶 、 amberlyst-15 、 sodium acetate 、 sodium hydride 、 三乙胺 作用下, 以 四氢呋喃甲醇四氯化碳氯仿N,N-二甲基甲酰胺 为溶剂, 反应 56.5h, 生成 [3-(bromomethyl)phenyl] [2-methoxy-3-(4-phenylmethoxyphenoxy)propyl] hydrogen phosphate
    参考文献:
    名称:
    Analogs of platelet activating factor. 6. Mono- and bis-aryl phosphate antagonists of platelet activating factor
    摘要:
    A series of aryl phosphoglyceride (3, 19-6 1) and bis-aryl phosphate (67-135) antagonists of platelet activating factor (PAF) were prepared. A group of four bifunctional phosphorus reagents (5a-c and 7) were developed that allowed the preparation of these aryl phosphates in which the position of aromatic substitution can be varied. These compounds were examined for their ability to inhibit PAF-induced platelet aggregation of rabbit platelets. Selected compounds were also evaluated for their ability to displace [H-3]PAF from its receptor on rabbit platelets. These in vitro data were compared to similar data obtained for a number of known PAF antagonists. The compounds were evaluated in vivo, in both the mouse and rabbit, for their ability to prevent death induced by a lethal challenge of PAF. The relationships between the biological activity and the nature, lipophilicity, and position of substituents of the aromatic rings were studied. Compound 105 (CL 184005) has been selected to undergo further development as a potential therapeutic agent for the treatment of septic shock in man.
    DOI:
    10.1021/jm00087a023
  • 作为产物:
    参考文献:
    名称:
    Antihypertensive phosphate derivatives
    摘要:
    所述具有以下结构的降压磷酸酯衍生物的描述:##STR1##其中X从以下组中选择:苯基基团,在任何位置用C.sub.1 -C.sub.20支链或直链烷氧基或苄氧基取代,并且可选地在任何其他位置用一个或多个由C.sub.1 -C.sub.15支链或直链烷基、C.sub.1 -C.sub.15支链或直链烷氧基和卤素组成的基团取代,以及在任何位置用C.sub.1 -C.sub.20支链或直链烷氧基或苄氧基取代的萘基基团,并且可选地在任何其他位置用一个或多个由C.sub.1 -C.sub.15支链或直链烷基、C.sub.1 -C.sub.15支链或直链烷氧基和卤素组成的基团取代;T从以下组中选择:氢和##STR2##其中R.sub.1从以下组中选择:氢、C.sub.1 -C.sub.4支链或直链烷基、C.sub.1 -C.sub.4支链或直链烷氧基和C.sub.1 -C.sub.4支链或直链烷基氨基;Y从双价基团组中选择:--(CH.sub.2).sub.p --和--(CHR).sub.p --,其中p是从2到10的整数,而基团--(CHR).sub.p --表示一个或多个C.sub.1 -C.sub.8烷基或苯基取代的烷基链;Z从以下组中选择:--N.sup.+ (R.sub.2).sub.3和##STR3##其中q是从4到7的整数,R.sub.2可以相同也可以不同,从以下组中选择:氢和C.sub.1 -C.sub.4支链或直链烷基。
    公开号:
    US04697031A1
点击查看最新优质反应信息

文献信息

  • Antihypertensive phosphate derivatives
    申请人:American Cyanamid Company
    公开号:US04697031A1
    公开(公告)日:1987-09-29
    Antihypertensive phosphate derivatives having the following formula are described: ##STR1## wherein X is selected from the group consisting of a phenyl radical substituted at any position with a C.sub.1 -C.sub.20 branched or straight chain alkoxy or benzyloxy and optionally substituted by any other positions with one or more groups consisting of C.sub.1 -C.sub.15 branched or straight chain alkyl, C.sub.1 -C.sub.15 branched or straight chain alkoxy and halogen, and a naphthalene radical substituted at any position with a C.sub.1 -C.sub.20 branched or straight chain alkoxy or benzyloxy and optionally substituted at any other positions with one or more groups consisting of C.sub.1 -C.sub.15 branched or straight chain alkyl, C.sub.1 -C.sub.15 branched or straight chain alkoxy and halogen; T is selected from the group consisting of hydrogen and ##STR2## wherein R.sub.1 is selected from the group consisting of hydrogen, C.sub.1 -C.sub.4 branched or straight chain alkyl, C.sub.1 -C.sub.4 branched or straight chain alkoxy and C.sub.1 -C.sub.4 branched or straight chain alkylamino; Y is selected from the group of bivalent radicals consisting of --(CH.sub.2).sub.p -- and --(CHR).sub.p --, wherein p is an integer from 2 to 10 and the moiety --(CHR).sub.p -- represents an alkylene chain substituted with one or more C.sub.1 -C.sub.8 alkyl groups or phenyl groups; Z is selected from the group consisting of --N.sup.+ (R.sub.2).sub.3 and ##STR3## wherein q is an integer from 4-7 and R.sub.2 may be the same or different and is selected from the group consisting of hydrogen and C.sub.1 -C.sub.4 branched or straight chain alkyl.
    所述具有以下结构的降压磷酸酯衍生物的描述:##STR1##其中X从以下组中选择:苯基基团,在任何位置用C.sub.1 -C.sub.20支链或直链烷氧基或苄氧基取代,并且可选地在任何其他位置用一个或多个由C.sub.1 -C.sub.15支链或直链烷基、C.sub.1 -C.sub.15支链或直链烷氧基和卤素组成的基团取代,以及在任何位置用C.sub.1 -C.sub.20支链或直链烷氧基或苄氧基取代的萘基基团,并且可选地在任何其他位置用一个或多个由C.sub.1 -C.sub.15支链或直链烷基、C.sub.1 -C.sub.15支链或直链烷氧基和卤素组成的基团取代;T从以下组中选择:氢和##STR2##其中R.sub.1从以下组中选择:氢、C.sub.1 -C.sub.4支链或直链烷基、C.sub.1 -C.sub.4支链或直链烷氧基和C.sub.1 -C.sub.4支链或直链烷基氨基;Y从双价基团组中选择:--(CH.sub.2).sub.p --和--(CHR).sub.p --,其中p是从2到10的整数,而基团--(CHR).sub.p --表示一个或多个C.sub.1 -C.sub.8烷基或苯基取代的烷基链;Z从以下组中选择:--N.sup.+ (R.sub.2).sub.3和##STR3##其中q是从4到7的整数,R.sub.2可以相同也可以不同,从以下组中选择:氢和C.sub.1 -C.sub.4支链或直链烷基。
  • Certain hydroxy-phosphinyl-oxy-phenyl methyl-thiazolium hydroxide inner
    申请人:American Cyanamid Company
    公开号:US05215975A1
    公开(公告)日:1993-06-01
    The invention is a compound of R or S enantiomers or racemic mixtures of compounds of the formula: ##STR1## wherein: (A) X is (i) C.sub.1 -C.sub.24 (ii) C.sub.1 -C.sub.24 alkoxy; (iii) C.sub.1 -C.sub.24 carboamoyloxy; ##STR2## wherein n is an integer from 1 to 25 and m is an integer from 0 to 24 and the sum of n and m is less than or equal to 25; (v) phenyl; (vi) mono-or polysubstituted phenyl substituted with C.sub.1 -C.sub.20 alkoxy, halogen, trifluoromethyl, phenyl, or benzyloxy; (vii) phenoxy; (viii) mono- or polysubstituted phenoxy substituted with C.sub.1 -C.sub.20 alkyl, C.sub.1 -C.sub.20 alkoxy, halogen, trifluoromethyl, phenyl, or benzyloxy; (ix) naphthaloxy; (x) mono- or polysubstituted naphthaloxy substituted with C.sub.1 -C.sub.20 alkyl, C.sub.1 -C.sub.20 alkoxy or halogen; (B) i is an integer from 1 to 3 and j is an integer from 1 to 6; (C) Q is --OR.sub.2, ##STR3## or O--C--R.sub.2, wherein R.sub.2 is hydrogen, C.sub.1 -C.sub.6 alkyl or C.sub.1 -C.sub.6 alkenyl; (D) Y is the divalent radical ##STR4## (E) the moiety R.sub.3 represents one or more C.sub.1 -C.sub.5 alkyl, C.sub.1 -C.sub.5 alkoxy or halogen substituents of the aromatic ring; (F) the moiety --CH.sub.2 A may be in the ortho, meta or para position wherein A is the (i) ##STR5## which are PAF inhibitors.
    这项发明是一种化合物,包括R或S对映体或式子的混合物:##STR1## 其中:(A)X是(i)C.sub.1-C.sub.24(ii)C.sub.1-C.sub.24烷氧基;(iii)C.sub.1-C.sub.24羧酰氧基;##STR2##其中n是1到25的整数,m是0到24的整数,n和m的和小于或等于25;(v)苯基;(vi)C.sub.1-C.sub.20烷氧基,卤素,三氟甲基,苯基或苄氧基取代的单取代或多取代苯基;(vii)苯氧基;(viii)C.sub.1-C.sub.20烷基,C.sub.1-C.sub.20烷氧基,卤素,三氟甲基,苯基或苄氧基取代的单取代或多取代苯氧基;(ix)萘氧基;(x)C.sub.1-C.sub.20烷基,C.sub.1-C.sub.20烷氧基或卤素取代的单取代或多取代萘氧基; (B)i是1到3的整数,j是1到6的整数;(C)Q是-OR.sub.2,##STR3##或O-C-R.sub.2,其中R.sub.2为氢,C.sub.1-C.sub.6烷基或C.sub.1-C.sub.6烯基;(D)Y是二价基团##STR4##(E)基团R.sub.3表示芳香环的一个或多个C.sub.1-C.sub.5烷基,C.sub.1-C.sub.5烷氧基或卤素取代基;(F)基团--CH.sub.2 A可以在邻位,间位或对位,其中A是(i)##STR5##这些是PAF抑制剂。
  • Novel antagonists of platelet activating factor
    申请人:AMERICAN CYANAMID COMPANY
    公开号:EP0336142A2
    公开(公告)日:1989-10-11
    The invention is a compound of R or S enantiomers or racemic mixtures of compounds of the formula: wherein: (A) X is (i) C1-C24 (ii) C1-C24 alkoxy; (iii) C1-C24 carboamoyloxy; or wherein n is an integer from 1 to 25 and m is an integer from 0 to 24 and the sum of n and m is less than or equal to 25; (v) phenyl; (vi) mono- or polysubstituted phenyl substituted with C1-C20 alkyl, C1-C20 alkoxy, halogen, trifluoromethyl, phenyl, substituted phenyl or benzyloxy; (vii) phenoxy; (viii) mono- or polysubstituted phenoxy substituted with C1-C20 alkyl, Ci-C2o alkoxy, halogen, trifluoromethyl, phenyl substituted phenyl or benzyloxy; (ix) naphthaloxy; (x) mono- or polysubstituted naphthaloxy substituted with C1-C20 alkyl, C1-C20 alkoxy or halogen; (xi) -O-(CH2)r-O-((CH2)pO)t-(CH2)a-W wherein W is methyl or phenyl optionally substituted with C,-C3 alkyl, C1-C3 alkoxy or phenyl, r, p, t and a are integers such that the expression r + (p + 1)t + a is also an integer and has a value of 3 to 20; r is greater than or equal to 2; p is greater than or equal to 2; t is greater than or equal to zero; and a is greater than or equal to zero; (B) i is an integer from 1 to 3 and j is an integer from 1 to 6; (C) Q is -OR2, or O-C-R2, wherein R2 is hydrogen, C1-C6 alkyl or C1-C6 alkenyl; (D) Y is a divalent radical or (E) the moiety R3 represents one or more C1-C5 alkyl, C1-C5 alkoxy or halogen substituents of the aromatic ring; (F) the moiety -CH2A may be in the ortho, meta or para position wherein A is (i) a 5-7 member aromatic heterocyclic ring containing at least one nitrogen and one or more nitrogen or sulfur atoms: (ii) or (iii) which are PAF inhibitors.
    本发明是一种 R 或 S 对映体的化合物或式中化合物的外消旋混合物: 其中 (A) X 是 (i) C1-C24 (ii) C1-C24 烷氧基 (iii) C1-C24 碳酰胺氧基; 或 其中 n 为 1 至 25 的整数,m 为 0 至 24 的整数,且 n 与 m 之和小于或等于 25; (v) 苯基 (vi) 被 C1-C20 烷基、C1-C20 烷氧基、卤素、三氟甲基、苯基、取代苯基 或苄氧基取代的单取代或多取代苯基; (vii) 苯氧基 (viii) 被 C1-C20 烷基、C1-C2o 烷氧基、卤素、三氟甲基、苯基、取代苯基 或苄氧基取代的单取代或多取代苯氧基; (ix) 萘氧基 (x) 被 C1-C20 烷基、C1-C20 烷氧基或卤素取代的单取代或多取代萘氧基; (xi) -O-(CH2)r-O-((CH2)pO)t-(CH2)a-W,其中 W 是甲基或任选被 C,-C3烷基、C1-C3 烷氧基或苯基取代的苯基,r、p、t 和 a 是整数,使得表达式 r + (p + 1)t + a 也是整数,且值为 3 至 20;r 大于或等于 2;p 大于或等于 2;t 大于或等于零;a 大于或等于零; (B) i 是 1 至 3 的整數,j 是 1 至 6 的整數; (C) Q 为-OR2、 或 O-C-R2,其中 R2 是氢、C1-C6 烷基或 C1-C6 烯基; (D) Y 是二价基 或 (E) 分子 R3 代表芳环的一个或多个 C1-C5 烷基、C1-C5 烷氧基或卤素取代基; (F) 分子 -CH2A 可位于正位、偏位或对位,其中 A 是 (i) 包含至少一个氮原子和一个或多个氮或硫原子的 5-7 个芳香杂环: (ii) 或 (iii) 或 是 PAF 抑制剂。
  • Okamoto, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1954, vol. 74, p. 1069,1071
    作者:Okamoto
    DOI:——
    日期:——
  • US4697031A
    申请人:——
    公开号:US4697031A
    公开(公告)日:1987-09-29
查看更多